What is DNA's health score?

Ginkgo Bioworks Holdings, Inc. (DNA) has a TradeApes health score of 33 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is DNA's estimated fair value?

Based on our 5-year discounted cash flow model, Ginkgo Bioworks Holdings, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is DNA undervalued or overvalued?

Our model currently rates DNA as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for DNA... Refresh in a moment for the full analysis.

Ginkgo Bioworks Holdings, Inc. (DNA)

Healthcare Inconclusive inconclusive weak

$9.05

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

40 Weak

Relative Value

20 Stressed

Capital Allocation

30 Weak

Risk

50 Mixed

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Extreme P/E — above 45×, very high expectations embedded in price

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.